Intralesional therapy as a treatment for locoregionally metastatic melanoma

Expert Review of Anticancer Therapy
John T Miura, Jonathan S Zager

Abstract

The emergence of novel intralesional therapies have dramatically changed the treatment landscape for melanoma. The heterogeneous presentation of melanoma continues to pose challenges for clinicians, especially when dealing with advanced locoregional disease. Intralesional therapies have the benefit of causing local tumor destruction, while minimizing systemic toxicity. Moreover, the integration of immunotherapeutic agents into intralesional compounds has resulted in the additional benefit of a bystander effect, whereby untreated distant lesions also derive a benefit from treatment. Intralesional therapy has assumed an important role in the management of unresectable, locoregional disease for melanoma. Areas covered: Multiple intralesional agents have been studied over the years, with only a few demonstrating promising results. This review will provide an overview of the different intralesional agents for melanoma. Mechanisms of action, clinical efficacy, and side effects will be the primary focus. Expert commentary: Treatment options for advanced melanoma continue to evolve. Attractive new therapies delivered by an intralesional route has demonstrated promising results, with minimal side effects. The ideal treatment strategy fo...Continue Reading

References

Nov 1, 1976·Archives of Ophthalmology·R J MarshJ I McGill
Jan 1, 1977·Journal of Surgical Oncology·J C Robinson
Jun 1, 1976·Archives of Surgery·C P KarakousisE D Holyoke
May 1, 1976·The Medical Clinics of North America·D W Weiss
Jun 22, 1984·Science·D A Cantrell, K A Smith
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G E PlautzG J Nabel
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T StopeckS Stahl
Aug 21, 2001·The Journal of Investigative Dermatology·C HoellerH Pehamberger
Oct 31, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·L RidolfiM G Righini
Aug 1, 1960·Proceedings of the Society for Experimental Biology and Medicine·R H KUBINJ V CARBONE
Jan 1, 2005·Current Opinion in Oncology·John W Eklund, Timothy M Kuzel
Feb 17, 2005·Melanoma Research·Christopher M ByrneWilliam H McCarthy
Nov 23, 2006·Melanoma Research·Rene GonzalezPaul O Schwarzenberger
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer C C HuR Charles Coombes
May 15, 2008·Expert Opinion on Biological Therapy·Agop Y Bedikian, Michele Del Vecchio
Oct 3, 2008·Melanoma Research·John F ThompsonEric Wachter
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil N SenzerJohn J Nemunaitis
Jul 12, 2011·Journal of Surgical Oncology·Kirsty U BoydClaire L F Temple
Aug 23, 2011·Journal of Surgical Oncology·Alessandro TestoriJavier Soteldo
Sep 18, 2012·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·B MaliD Miklavcic
Mar 5, 2013·Annals of Surgical Oncology·Joyce WongJonathan S Zager
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Dec 5, 2013·Journal of Surgical Oncology·Peter Hersey, Stuart Gallagher
Jan 24, 2014·Journal of Surgical Oncology·Claire F Temple-OberleJ Gregory McKinnon
Feb 11, 2014·Journal of Surgical Oncology·Merrick I Ross
Jun 28, 2014·Journal for Immunotherapy of Cancer·Howard L KaufmanCraig L Slingluff
Jul 6, 2014·Journal of Surgical Oncology·Brett A ByersJ Greg McKinnon
Oct 29, 2014·Annals of Surgical Oncology·John F ThompsonEric A Wachter
Jan 30, 2015·Current Opinion in Oncology·Sanjiv S Agarwala
May 15, 2015·Cancer Immunology, Immunotherapy : CII·Riccardo DanielliMario Santinami
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Nov 20, 2015·Annals of Surgical Oncology·Hidde M KroonJohn F Thompson

❮ Previous
Next ❯

Citations

Sep 21, 2019·Future Oncology·John T Miura, Jonathan S Zager
Oct 10, 2018·Annals of Surgical Oncology·Matthew C PerezJonathan S Zager
Dec 15, 2018·Journal of Surgical Oncology·Jennifer M RaczJames W Jakub
Nov 23, 2019·The Surgical Clinics of North America·David T Pointer, Jonathan S Zager

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Pharmacotherapy
Sarah SlootJonathan S Zager
Expert Opinion on Biological Therapy
Carrie LuuJonathan S Zager
The Journal of Community and Supportive Oncology
Katja A Schindler, Michael A Postow
BMJ : British Medical Journal
Chante KarimkhaniSrinath Sundararajan
© 2022 Meta ULC. All rights reserved